PharmaCyte director fixes cancelled option grant

WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.

PharmaCyte Biotech, Inc. director Wayne Remell Walker reported an administrative correction to a prior stock option grant. The footnote explains that the grant was made in error and has been cancelled, leaving 0.0000 derivative securities from this grant and no common stock bought or sold.

Insider Trade Summary

Other: 0 shares

Other 1 txn

Insider WALKER WAYNE REMELL

Role Director

Type	Security	Shares	Price	Value
Other	Stock Option (Right to Buy) F1	0	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct)

Footnotes (1)

1. F1. The reported grant was made in error and has been cancelled.

Key Figures

Derivative securities after correction: 0.0000 Transaction date: 2026-03-31 Net common shares traded: 0

3 metrics

Derivative securities after correction 0.0000 Stock Option (Right to Buy) position after erroneous grant was cancelled

Transaction date 2026-03-31 Date associated with the corrected derivative transaction entry

Net common shares traded 0 No PMCB common stock purchases or sales reported in this amendment

Key Terms

Stock Option (Right to Buy), Other acquisition or disposition, derivative securities

3 terms

Stock Option (Right to Buy) financial

"The security title is reported as "Stock Option (Right to Buy)"."

Other acquisition or disposition financial

"The transaction code description is "Other acquisition or disposition"."

derivative securities financial

"The filing classifies the option as derivative securities with 0.0000 remaining."

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PharmaCyte Biotech (PMCB) director Wayne Remell Walker report in this Form 4/A?

He reported an administrative correction to a previously reported stock option grant. A footnote states the grant was made in error and has been cancelled, with no common shares purchased or sold in connection with this amendment.

Did Wayne Remell Walker buy or sell PMCB common stock in this insider filing?

No common stock was bought or sold. The only entry is a derivative “Stock Option (Right to Buy)” line showing 0.0000 securities after cancellation of an erroneously reported grant, so there is no reported trading in PMCB shares.

What does the footnote in Wayne Remell Walker’s PMCB Form 4/A say?

The footnote states that “The reported grant was made in error and has been cancelled.” This means the option award previously reported is no longer outstanding, and the corrected line reflects that cancellation with zero derivative securities remaining.

How many PharmaCyte Biotech derivative securities does Wayne Remell Walker show after this correction?

For the reported “Stock Option (Right to Buy)” entry, the post-transaction amount is 0.0000 derivative securities. This aligns with the footnote that the grant was made in error and cancelled, so no options from that grant remain outstanding.

What is the transaction date of the corrected PMCB option entry for Wayne Remell Walker?

The corrected derivative entry uses a transaction date of 2026-03-31. On that date, the report characterizes the event as an “Other acquisition or disposition,” tied to cancelling an erroneously granted stock option with no net share activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALKER WAYNE REMELL

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/02/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	(1)	03/31/2026(1)		J(1)		0(1)		(1)	(1)	Common Stock(1)	(1)	(1)	0(1)	D

Explanation of Responses:

1. The reported grant was made in error and has been cancelled.

	/s/ Wayne R. Walker	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)